Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.48 |
| ▸ | MDM4 | O15151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | TLR2 | O60603 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757411 | 1.00 | MDM2 (0.48) | MDM2MDM4TP53PTPN1TLR2 | |
| SCHEMBL23014552 | 1.00 | MDM2 (0.48) | MDM2MDM4TP53PTPN1TLR2 | |
| SCHEMBL29547181 | 0.90 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29792115 | 0.90 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL2288397 | 0.90 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31681399 | 0.90 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL6158363 | 0.90 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29362301 | 0.90 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL436024 | 0.90 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31212515 | 0.89 | MDM2 (0.51) | MDM2MDM4TP53PTPN1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | ELI LILLY AND COMPANY | 2022-12-29 | — | — | US | disclosed |
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | ELI LILLY AND COMPANY | 2022-12-29 | — | — | US | disclosed |
| EP-4017866-A1 | METHODS OF MAKING INCRETIN ANALOGS | Eli Lilly and Company (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114269775-A | Preparation method of incretin analogue | 伊莱利利公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021034815-A1 | METHODS OF MAKING INCRETIN ANALOGS | ELI LILLY AND COMPANY (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021034815-A1 | METHODS OF MAKING INCRETIN ANALOGS | ELI LILLY AND COMPANY (US) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | IAPP, GLP1R, GIPR | MDM2 2077/4885MDM4 4057/4885TP53 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.